BD Invests $100 Million to Expand Insulin Syringe Manufacturing

BD (Becton, Dickinson and Company), a global medical technology company, today announced it is investing $100 million in its Holdrege, Neb. facility to expand capacity for its insulin syringe manufacturing operations.
 
The investment will be used for new technology and manufacturing equipment to expand capacity for BD insulin syringes. BD already produces more than 2 billion insulin syringes each year, which averages to be more than 250,000 syringes per hour.
 
“About 40 percent of people with diabetes who inject insulin use syringes as part of their diabetes management regimen,” said Ken Miller, worldwide president of Diabetes Care for BD. “This investment will provide benefits to this diabetes population and underscores our commitment to supply high-quality, industry-leading insulin syringes to patients.”
 
BD began operations in Holdrege in 1966 in a 12,000 square foot building with 66 associates. Today, the facility has grown to 350,000 square feet with more than 650 associates manufacturing 20 different BD products. BD is the largest employer in Phelps County. Across Nebraska, BD employs more than 2,500 associates in four manufacturing facilities in Holdrege, Broken Bow and two in Columbus.